Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2022 17:00 ET
|
Olema Oncology
SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer
January 31, 2022 07:30 ET
|
Olema Oncology
• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela...
Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief...
Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer
November 30, 2021 07:00 ET
|
Olema Oncology
Successful completion of dose-escalation stage of ongoing Phase 1/2 clinical study; OP-1250 demonstrated highly attractive pharmacokinetics, favorable tolerability, and clear efficacy signalsRobust...
Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media
November 29, 2021 16:27 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium
November 22, 2021 07:30 ET
|
Olema Oncology
Interim pharmacokinetic, safety and tolerability, and preliminary efficacy data from Phase 1 dose escalation to be presented Company to host investor webcast at 8:30 a.m. ET on Wednesday, December 8,...
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 16:05 ET
|
Olema Oncology
Completed dose-escalation stage of Phase 1/2 clinical trial of OP-1250 in patients with metastatic, ER+ / HER2- breast cancerInterim safety, tolerability, pharmacokinetic and initial efficacy data...
Olema Oncology to Present at Two Upcoming Investor Conferences
November 09, 2021 07:30 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021 17:00 ET
|
Olema Oncology
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference
September 09, 2021 07:30 ET
|
Olema Oncology
SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...